Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

Department of Chemistry moves into world-class facilities
2008-05-16

 

Attending the opening of the first and second phases of the Department of Chemistry's upgraded research facilities on the Main Campus of the UFS in Bloemfontein are, from the left: Prof. André Roodt, Head of the department, Prof. Herman van Schalkwyk, Dean: Faculty of Natural and Agricultural Sciences at the UFS, and Ms Tania van Zyl, Architect from Goldblatt Yuill Architects in Bloemfontein.
Photo: Leonie Bolleurs

UFS Department of Chemistry moves into world-class facilities

The University of the Free State’s (UFS) Department of Chemistry recently moved into the first and second phases of the southern wing of the upgraded Moerdyk and annex building in which the department is situated. The wing is part an extensive project to upgrade the building and its facilities.

At a total costs of R40 million for the upgrading of the building and R30 million for the equipment, this is the biggest project of its kind in the history of the UFS.

The upgrading is taking place in four phases, of which the largest part is the southern wing. Researchers and undergraduate students recently moved into this part of the building, which consists of the first- and second-year laboratories. The laboratories consist of, among others, larger and safer venting and research-focused facilities as well as enough storage for the department’s equipment. Although one of the water-cooling systems on the roof of the building recently caught fire, all classes, practical and research work is going ahead without any disturbance.

“The putting into service of the first two phases is a milestone for the department. The project is almost half way and, when it is completed by the middle to end of 2009, we will boast with some of the best research and undergraduate laboratories in the country. It will also increase our leadership in advanced training on the continent and will strengthen the UFS’s role in the international chemistry arena,” says Prof. André Roodt, head of the department.

According to Prof. Roodt advanced research on fuel and nano particles (this is particles as big as one hundred thousandth of a human hair strand) will be conducted in the completed laboratories as part of the UFS’s research cluster initiative. Other research such as anti cancer remedies, research on various chemical processes and research on biological pharmacological remedies will also be done.

“During the past three years the department has made a significant impact on research in chemistry worldwide. Our academics are publishing in some of the world’s foremost chemistry journals and various presentations are made at international conferences. The upgraded facilities will ensure that we continue building on our high quality research and it will also ensure that our students can compete with the best in the world,” says Prof. Roodt.

Media Release
Issued by: Lacea Loader
Assistant Director: Media Liaison
Tel: 051 401 2584
Cell: 083 645 2454
E-mail: loaderl.stg@ufs.ac.za  
16 May 2008

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept